文献速递湿疹皮炎与荨麻疹

特应性皮炎的系统性免疫调节治疗:动态系统评价与网状Meta分析的更新

Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2022-01-01

本动态系统评价与网状Meta分析纳入60项随机临床试验、共16579例中重度特应性皮炎患者,比较系统性免疫调节药物的疗效与安全性。成人治疗至16周时,阿布昔替尼200mg/日与乌帕替尼30mg/日降低EASI略优于度普利尤单抗,乌帕替尼15mg/日与度普利尤单抗相近,阿布昔替尼100mg/日、巴瑞替尼4mg与2mg/日及曲罗芦单抗降低EASI略逊于度普利尤单抗。

要点

  • 阿布昔替尼200mg/日与乌帕替尼30mg/日降低EASI略优于度普利尤单抗,证据确定性高。
  • 乌帕替尼15mg/日与度普利尤单抗相比EASI变化无重要差异,证据确定性高。
  • 阿布昔替尼100mg/日、巴瑞替尼4mg与2mg/日及曲罗芦单抗降低EASI略逊于度普利尤单抗。

核心结论

  • 阿布昔替尼200mg/日与乌帕替尼30mg/日评分略优于度普利尤单抗,乌帕替尼15mg/日与度普利尤单抗相近。
  • 阿布昔替尼100mg/日、巴瑞替尼4mg与2mg/日及曲罗芦单抗每2周300mg评分略差。

研究设计与样本

  • 动态系统评价与网状Meta分析,检索Cochrane对照试验中心注册库、MEDLINE、Embase、LILACS、GREAT数据库及试验注册库至2021年6月15日。
  • 纳入治疗8周及以上、针对中重度特应性皮炎的系统性免疫调节药物随机临床试验,自2019年10月以来新增21项研究,共60项试验、16579例患者。
  • 采用贝叶斯网状Meta分析,并评估GRADE证据确定性,更新分析于2021年6月至12月完成。

主要发现

  • 成人治疗至16周,阿布昔替尼200mg/日降低EASI略多于度普利尤单抗(首剂600mg后每2周300mg),MD 2.2(95%CrI 0.2-4.0),证据确定性高。
  • 乌帕替尼30mg/日降低EASI略多于度普利尤单抗,MD 2.7(95%CrI 0.6-4.7),证据确定性高。
  • 阿布昔替尼100mg/日降低EASI略少于度普利尤单抗,MD -2.1(95%CrI -4.1至-0.3),证据确定性高。
  • 巴瑞替尼4mg/日与2mg/日降低EASI略少于度普利尤单抗,MD分别为-3.2(95%CrI -5.7至-0.8)与-5.2(95%CrI -7.5至-2.9),证据确定性高。
  • 曲罗芦单抗首剂600mg后每2周300mg降低EASI略少于度普利尤单抗,MD -3.5(95%CrI -5.8至-1.3),证据确定性高。

关键数值与推荐

  • 乌帕替尼15mg/日与度普利尤单抗相比EASI变化差异很小或无差异,MD 0.2(95%CrI -1.9至2.2),证据确定性高。
  • POEM、DLQI与PP-NRS的结果模式与EASI相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Systemic treatments for atopic dermatitis are being evaluated primarily in placebo-controlled trials; network meta-analysis can provide relative efficacy and safety estimates for treatments that have not been compared head to head. OBJECTIVE: To compare reported measures of efficacy and assessments of safety in clinical trials of systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis. DATA SOURCES: The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Latin American and Caribbean Health Science Information database, Global Resource of EczemA Trials database, and trial registries were searched through June 15, 2021. STUDY SELECTION: Randomized clinical trials examining 8 or more weeks of treatment with systemic immunomodulatory medications for moderate-to-severe atopic dermatitis were included after screening titles, abstracts, and papers in duplicate. DATA EXTRACTION AND SYNTHESIS: Data were abstracted in duplicate. Bayesian network meta-analyses and assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed. The updated analysis was completed from June to December 2021. MAIN OUTCOMES AND MEASURES: Outcomes include change in Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS). RESULTS: Since October 2019, 21 new studies were added, for a total of 60 trials with 16 579 patients. Up to 16 weeks of treatment in adults, abrocitinib, 200 mg daily (mean difference [MD], 2.2; 95% credible interval [CrI], 0.2-4.0; high certainty) and upadacitinib, 30 mg daily (MD, 2.7; 95% CrI, 0.6-4.7; high certainty) were associated with reduced EASI slightly more than dupilumab, 600 mg then 300 mg every 2 weeks. Abrocitinib, 100 mg daily (MD, -2.1; 95% CrI, -4.1 to -0.3; high certainty), baricitinib, 4 mg daily (MD, -3.2; 95% CrI, -5.7 to -0.8; high certainty), baricitinib, 2 mg daily (MD, -5.2; 95% CrI, -7.5 to -2.9; high certainty) and tralokinumab, 600 mg then 300 mg every 2 weeks (MD, -3.5; 95% CrI, -5.8 to -1.3; high certainty) were associated with reduced EASI slightly less than dupilumab. There was little or no difference between upadacitinib, 15 mg daily, and dupilumab (MD, 0.2; 95% CrI, -1.9 to 2.2; high certainty). The pattern of results was similar for POEM, DLQI, and PP-NRS. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, abrocitinib, 200 mg; and upadacitinib, 30 mg daily, were associated with slightly better scores than dupilumab, and upadacitinib, 15 mg daily, was associated with similar scores to dupilumab. Abrocitinib, 100 mg daily, baricitinib, 4 mg and 2 mg daily, and tralokinumab, 300 mg, every 2 weeks were associated with slightly worse scores.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA Dermatol. 2022. PMID: 35293977. doi:10.1001/jamadermatol.2022.0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。